According to Incyte's latest financial reports the company has ยฃ1.80 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | ยฃ1.71 B | -40.07% |
2023-12-31 | ยฃ2.86 B | 7.19% |
2022-12-31 | ยฃ2.67 B | 53.9% |
2021-12-31 | ยฃ1.73 B | 31.63% |
2020-12-31 | ยฃ1.32 B | -18.16% |
2019-12-31 | ยฃ1.61 B | 42.51% |
2018-12-31 | ยฃ1.13 B | 30.93% |
2017-12-31 | ยฃ0.86 B | 32.07% |
2016-12-31 | ยฃ0.65 B | 37.2% |
2015-12-31 | ยฃ0.47 B | 23.88% |
2014-12-31 | ยฃ0.38 B | 24.94% |
2013-12-31 | ยฃ0.30 B | 118.35% |
2012-12-31 | ยฃ0.14 B | -20.87% |
2011-12-31 | ยฃ0.17 B | -35% |
2010-12-31 | ยฃ0.27 B | -5.48% |
2009-12-31 | ยฃ0.29 B | 115.16% |
2008-12-31 | ยฃ0.13 B | 4.68% |
2007-12-31 | ยฃ0.12 B | -20.64% |
2006-12-31 | ยฃ0.16 B | -18.7% |
2005-12-31 | ยฃ0.20 B | -18.25% |
2004-12-31 | ยฃ0.24 B | 48.98% |
2003-12-31 | ยฃ0.16 B | -38.61% |
2002-12-31 | ยฃ0.26 B | -23.62% |
2001-12-31 | ยฃ0.35 B | -10.19% |
2000-12-31 | ยฃ0.39 B | 842.12% |
1999-12-31 | ยฃ41.4 M | -38.09% |
1998-12-31 | ยฃ66.87 M | 97.58% |
1997-12-31 | ยฃ33.84 M | 662.58% |
1996-12-31 | ยฃ4.43 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Amgen AMGN | ยฃ6.59 B | 265.76% | ๐บ๐ธ USA |
![]() Ligand Pharmaceuticals LGND | ยฃ0.15 B | -91.33% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | ยฃ2.41 B | 33.71% | ๐บ๐ธ USA |
![]() Pfizer PFE | ยฃ12.96 B | 618.91% | ๐บ๐ธ USA |
![]() Geron GERN | ยฃ0.29 B | -83.52% | ๐บ๐ธ USA |
![]() Ardelyx ARDX | ยฃ0.16 B | -91.12% | ๐บ๐ธ USA |
![]() Novartis NVS | ยฃ5.38 B | 198.76% | ๐จ๐ญ Switzerland |
![]() AVEO Oncology
AVEO | ยฃ57.93 M | -96.79% | ๐บ๐ธ USA |
![]() CTI BioPharma
CTIC | ยฃ44.16 M | -97.55% | ๐บ๐ธ USA |